Atrasentan Tied to Lower Risk for Kidney Events in T2DM With CKD

Atrasentan Tied to Lower Risk for Kidney Events in T2DM With CKD

Reduced risk seen for primary composite renal end point event; more frequent fluid retention, anemia reported

2019-05-09T16:26:29+00:00

Leave A Comment